Table 1. Summary of the literature about ESR1_TA, ESR2_CA, and AR_CAG microsatellites and breast cancer risk.

Author, year	Study type	Major population	Affected/Unaffected	Sample notes	DNA	Major dichotomous repeat cutoff	Main findings
ESR1_TA
Wedrén, 2004 [14]	Case-control	Swedish	1514/1514	Female, postmenopausal	Somatic, germline	14	Deviance from HWE
Iobagiu, 2006 [15]	Case-control	French	139/145	Female	Germline	19	No association
Anghel, 2006 [24]	Case-control	Romanian	153/318	Female	Somatic, germline	16, 23, 38 (sum)	Shorter repeats higher risk
Tsezou, 2008 [16]	Case-control	Greek	79/155	Female	Germline	15	No association
ESR2_CA
Försti, 2003 [23]	Case-control	Finnish	219/248	Female cases and male controls	Germline	NA	No association
Iobagiu, 2006 [15]	Case-control	French	139/145	Female	Germline	22	No association
Anghel, 2006 [24]	Case-control	Romanian	153/318	Female	Somatic, germline	22, 23, 45 (sum)	Shorter repeats higher risk
Tsezou, 2008 [16]	Case-control	Greek	79/155	Female	Germline	20	Longer repeats less risk
AR_CAG
Rebbec, 1999 [28]	Case-control	American	165/139	Female, BRCA1 mutation carriers	Germline	28	Longer repeats higher risk and earlier diagnosis
Spurdle, 1999 [29]	Case-control	Australian	368/284	Female, <40 years	Germline	22	No association overall, or stratified by family history, ER and PR status
Dunning, 1999 [30]	Case-control	British	508/426	Female	Germline	21, 28	No association
Young, 2000 [31]	Case-control	Scotch	59/79	Male	Somatic, germline	NA	No association
Given, 2000 [32]	Case only	Irish	178/−	Female, ≤65 years	Germline	28	No association
Yu, 2000 [33]	Case only	Italian	133/−	Female	Somatic	21, 44 (sum)	Longer repeats associated with lower grade of tumors, fewer lymph node metastases and longer survival
Menin, 2001 [34]	Case only	Italian	101+50/−	Some BRCA1/2 mutation carriers, 50 ovarian cancers	Germline	19, 23	No association
Kadouri, 2001 [35]	Case-control	Ashkenazi Jewish	152+166/36+152	Female, 188 BRCA1/2 mutation carriers including ovarian cancers	Germline	28	No association
Giguèr, 2001 [36]	Case-control	French-Canadian	255/461	Female	Germline	20, 39 (sum)	Shoter repeats less risk, association stronger in postmenopausal women
Elhaji, 2001 [37]	Case-control	Canadian	114/248	Female, >40 years	Somatic, germline	26	Longer repeats higher risk in well and moderately differential tumors
Kristiansen, 2002 [38]	Case-control	Norwegian	216/575	Female, heterozygous cases for the CAG repeat	Germline	30	No association
Haiman, 2002 [39]	Case-control	European-American	727/969	Female, predominantly postmenopausal	Germline	22	No association overall, longer repeats associated with family history
Dagan, 2002 [40]	Case-control	Israeli Jewish	108+41/78	Female, BRCA1/2 mutation carriers, 41 ovarian cancers	Germline	18, 19	Shorter repeats earlier onset
Suter, 2003 [41]	Case-control	European-American	524/461	Female, <45 years	Germline	22, 43 (sum)	Longer repeats higher risk, homozygous of CAG short allele associated with ever use of oral contraceptives
Syrjäkoski, 2003 [42]	Case only	Finnish	32/−	Male	Germline	NA	No association
Liede, 2003 [43]	Case-control	Filipino	299/229	Female	Germline	25	Longer repeats higher risk
MacLean, 2004 [44]	Case only	Australian	41/−	Male	Somatic	24	Longer repeats are more frequent in patients with grade I and II tumors, but not associated with age at diagnosis
Spurdle, 2004 [45]	Case-control	Australian & British	331+32/241	Female, BRCA1/2 mutation carriers, 32 ovarian caners	Germline	28, 29	No association
Wang, 2005 [9]	Case-control	African-American	239/	Female	Germline	22	No association overall, longer repeats associated with family history
Iobagiu, 2006 [15]	Case-control	French	249139/145	Female	Germline	15	Shorter repeats higher risk
Anghel, 2006 [24]	Case-control	Romanian	153/318	Female	Somatic, germline	13, 16, 28 (sum)	Longer repeats higher risk
Cox, 2006 [27]	Case-control	European-American & European	95+376+669/540+674	Female	Germline	22, 23, 25, 27	No association
Slattery, 2007 [46]	Case-control	European-American & Hispanic-American	1,169+576/1,330+725	Female	Germline	22	No association
González, 2007 [47]	Case-control	Spanish	257/393	Female	Germline	22	Longer repeats higher risk
Wedrén, 2007 [48]	Case-control	Swedish	1,542/1,511	Female, postmenopausal	Somatic, germline	22, 20	No association overall
Tsezou, 2008 [16]	Case-control	Greek	79/155	Female	Germline	22	Longer repeats less risk
Wu, 2008 [49]	Case-control	Taiwanese	88/334	Female	Germline	22	Longer repeats associated with short duration of early estrogen exposure
Abbas, 2010 [50]	Case-control	Germany	3,149/5,489	Female	Germline	22	Shorter repeats associated with combined estrogen-progestagen therapy
Chintamani, 2010 [51]	Case-control	Indian	70/80	Female	Germline	NA	No association
Sakoda, 2010 [52]	Case-control	Chinese	614+467/879	Female, 467 subjects with fibrocystic conditions	Germline	22–24	Longer repeats associated with an increased risk of fibrocystic breast conditions
Hietala, 2010 [53]	htSNP/diplotype	Swedish	56/269	Female, 56 BRCA1/2 mutation carriers and 269 young healthy subjects from breast cancer high-risk families	Germline	22	Neither individual htSNPs nor other diplotypes were significantly associated with androgen levels and did not tag for AR microsatellites
Rajender, 2010 [54]	Case-control	Indian	747/661	Female	Germline	NA	No association overall, no significant difference between pre- and post-menopausal cases
Mehdipour, 2010 [55]	Case-control	Iranian	500/432	Female	Germline	22	Longer repeats higher risk, but reduce the risk in subjects with positive family history
Gilbert, 2011 [56], [57]	Case-control	Egyptian	44/43	Male	Somatic, germline	14, 22	No association